EPPK1

Epiplakin je protein koji je kod ljudi kodiran genom EPPK1. Pripada porodici plakinskih proteina i nalazi se u ljudskoj epidermi. Sastoji se od 13 domena, od kojih su svi slični domenu B koji se nalazi na C-kraju ljudske epiderme i srčanomišićnog proteina dezmoplakina. Domeni u epiplakinu kreću se od 46-70% u homologiji ovog B domena u dezmoplakinu. Prvi put je identificiran kao autoantigen kod osobe koja boluje od rijetke autoimunske kožne bolesti. Epiplakin je sekvenciran tako da ima ukupno 5.065 aminokiselinskih ostataka i, na osnovu aminokiselinskog sastava, ima molekulsku masu od oko 552 kDa. Gen EPPK1 je značajan po nedostatku introna u svom kodirajućem području - cijelo njegovo kodirajuće područje od 15 kbp kodirano je jednim exon.

EPPK1
Identifikatori
Aliasi	EPPK1
Vanjski ID-jevi	OMIM: 607553 MGI: 2386306 HomoloGene: 20006 GeneCards: EPPK1
Lokacija gena (čovjek) Hrom. Hromosom 8 (čovjek) Bend 8q24.3 Početak 143,857,324 bp Kraj 143,878,467 bp
Ontologija gena Molekularna funkcija • vezivanje sa RNK • cytoskeletal protein binding • intermediate filament binding • structural molecule activity • keratin filament binding Ćelijska komponenta • citoplazma • citoskelet • ćelijska membrana • bicellular tight junction • membrana • basolateral plasma membrane • apicolateral plasma membrane • međućelijske veze • Hemidezmosom • projekcija ćelije • keratin filament • cell periphery • perinucleolar compartment • Intermedijarni filament Biološki proces • negative regulation of keratinocyte proliferation • negative regulation of cell migration • Zarastanje rana • intermediate filament organization • negative regulation of epithelial cell proliferation • negative regulation of keratinocyte migration • negative regulation of wound healing • regulation of epithelium regeneration • cytoskeleton organization • intermediate filament cytoskeleton organization • intermediate filament bundle assembly Izvori:Amigo / QuickGO
Ortolozi
Vrste	Čovjek	Miš
Entrez	83481	223650
Ensembl	ENSG00000261150	ENSMUSG00000115388
UniProt	P58107	Q8R0W0
RefSeq (mRNK)	NM_031308	NM_144848
RefSeq (bjelančevina)	NP_112598	NP_659097
Lokacija (UCSC)	Chr 8: 143.86 – 143.88 Mb	n/a
PubMed pretraga
Wikipodaci
Pogledaj/uredi – čovjek Pogledaj/uredi – miš

Aminokiselinska sekvenca

Dužina polipeptidnog lanca je 5.090 aminokiselina, а molekulska težina 555.621 Da.

10		20		30		40		50
MSGHTLPPLP		VPGTNSTEQA		SVPRAMAATL		GAGTPPRPQA		RSIAGVYVEA
SGQAQSVYAA		MEQGLLPAGL		GQALLEAQAA		TGGLVDLARG		QLLPVSKALQ
QGLVGLELKE		KLLAAERATT		GYPDPYGGEK		LALFQAIGKE		VVDRALGQSW
LEVQLATGGL		VDPAQGVLVA		PEPACHQGLL		DRETWHKLSE		LEPGTGDLRF
LNPNTLERLT		YHQLLERCVR		APGSGLALLP		LKITFRSMGG		AVSAAELLEV
GILDEQAVQG		LREGRLAAVD		VSARAEVRRY		LEGTGSVAGV		VLLPEGHKKS
FFQAATEHLL		PMGTALPLLE		AQAATHTLVD		PITGQRLWVD		EAVRAGLVSP
ELHEQLLVAE		QAVTGHHDPF		SGSQIPLFQA		MKKGLVDRPL		ALRLLDAQLA
TGGLVCPARR		LRLPLEAALR		CGCLDEDTQR		QLSQAGSFSD		GTHGGLRYEQ
LLALCVTDPE		TGLAFLPLSG		GPRGGEPQGP		PFIKYSTRQA		LSTATATVSV
GKFRGRPVSL		WELLFSEAIS		SEQRAMLAQQ		YQEGTLSVEK		LAAELSATLE
QAAATARVTF		SGLRDTVTPG		ELLKAEIIDQ		DLYERLEHGQ		ATAKDVGSLA
SAQRYLQGTG		CIAGLLLPGS		QERLSIYEAR		CKGLLRPGTA		LILLEAQAAT
GFIIDPKANK		GHSVEEALRA		AVIGPDVFAK		LLSAERAVTG		YTDPYTGQQI
SLFQAMQKGL		IVREHGIRLL		EAQIATGGVI		DPVHSHRVPV		DVAYRRGYFD
QMLNLILLDP		SDDTKGFFDP		NTHENLTYLQ		LLERCVRDPE		TGLYLLPLSS
TQSPLVDSAT		QQAFQNLLLS		VKYGRFQGQR		VSAWELINSE		YFSEGRRRQL
LRRYRQREVT		LGQVAKLLEA		ETQRQADIML		PALRSRVTVH		QLLEAGIIDQ
QLLDQVLAGT		ISPEALLLMD		GVRRYLCGLG		AVGGVRLLPS		GQRLSLYQAM
RQKLLGPRVA		LALLEAQAAT		GTIMDPHSPE		SLSVDEAVRR		GVVGPELYGR
LKRAEGAIAG		FRDPFSGKQV		SVFQAMKKGL		IPWEQAARLL		EAQVATGGII
DPTSHHHLPM		PVAIQRGYVD		QEMETALSSS		SETFPTPDGQ		GRTSYAQLLE
ECPRDETSGL		HLLPLPESAP		ALPTEEQVQR		SLQAVPGAKD		GTSLWDLLSS
CHFTEEQRRG		LLEDVQEGRT		TVPQLLASVQ		RWVQETKLLA		QARVMVPGPR
GEVPAVWLLD		AGIITQETLE		ALAQGTQSPA		QVAEQPAVKA		CLWGTGCVAG
VLLQPSGAKA		SIAQAVRDGL		LPTGLGQRLL		EAQVASGFLV		DPLNNQRLSV
EDAVKVGLVG		RELSEQLGQA		ERAAAGYPDP		YSRASLSLWQ		AMEKGLVPQN
EGLPLLQVQL		ATGGVVDPVH		GVHLPQAAAC		RLGLLDTQTS		QVLTAVDKDN
KFFFDPSARD		QVTYQQLRER		CVCDSETGLL		LLPLPSDTVL		EVDDHTAVAL
RAMKVPVSTG		RFKGCSVSLW		DLLLSEYVGA		DKRRELVALC		RSGRAAALRQ
VVSAVTALVE		AAERQPLQAT		FRGLRKQVSA		RDLFRAQLIS		RKTLDELSQG
TTTVKEVAEM		DSVKRSLEGG		NFIAGVLIQG		TQERMSIPEA		LRRHILRPGT
ALVLLEAQAA		TGFIIDPAEN		RKLTVEEAFK		AGMFGKETYV		KLLSAERAVT
GYTDPYTGQQ		ISLFQAMQKD		LIVREHGIRL		LEAQIATGGI		IDPVHSHRVP
VDVAYRCGYF		DEEMNRILAD		PSDDTKGFFD		PNTHENLTYL		QLLERCVEDP
ETGLYLLQII		KKGENYVYIN		EATRHVLQSR		TAKMRVGRFA		DQVVSFWDLL
SSPYFTEDRK		RELIQEYGAQ		SGGLEKLLEI		ITTTIEETET		QNQGIKVAAI
RGEVTAADLF		NSRVIDQKTL		HTLRVGRTGG		QALSTLECVK		PYLEGSDCIA
GVTVPSTREV		MSLHEASRKE		LIPAAFATWL		LEAQAATGFL		LDPCTRQKLS
VDEAVDVGLV		NEELRERLLK		AERAATGYRD		PATGDTIPLF		QAMQKQLIEK
AEALRLLEVQ		VATGGVIDPQ		HHHRLPLETA		YRRGCLHKDI		YALISDQKHM
RKRFVDPNTQ		EKVSYRELQE		RCRPQEDTGW		VLFPVNKAAR		DSEHIDDETR
RALEAEQVEI		TVGRFRGQKP		TLWALLNSEY		VTEEKKLQLV		RMYRTHTRRA
LQTVAQLILE		LIEKQETSNK		HLWFQGIRRQ		ITASELLSSA		IITEEMLQDL
ETGRSTTQEL		MEDDRVKRYL		EGTSCIAGVL		VPAKDQPGRQ		EKMSIYQAMW
KGVLRPGTAL		VLLEAQAATG		FVIDPVRNLR		LSVEEPVPAG		VVGSEIQEKL
LSAERAVTGY		TDPYTGQQIS		LFQAMQKDLI		VREHGIRLLE		AQIATGGVID
PVHSHRVPVD		VAYRRGYFDE		EMNRVLADPS		DDTKGFFDPN		THENLTYVQL
LRRCVPDPDT		GLYMLQLAGR		GSAVHQLSEE		LRCALRDARV		TPGSGALQGQ
SVSVWELLFY		REVSEDRRQD		LLSRYRAGTL		TVEELGATLT		SLLAQAQAQA
RAEAEAGSPR		PDPREALRAA		TMEVKVGRLR		GRAVPVWDVL		ASGYVSRAAR
EELLAEFGSG		TLDLPALTRR		LTAIIEEAEE		APGARPQLQD		ARRGPREPGP
AGRGDGDSGR		SQREGQGEGE		TQEAAAAAAA		ARRQEQTLRD		ATMEVQRGQF
QGRPVSVWDV		LFSSYLSEAR		RDELLAQHAA		GALGLPDLVA		VLTRVIEETE
ERLSKVSFRG		LRRQVSASEL		HTSGILGPET		LRDLAQGTKT		LQEVTEMDSV
KRYLEGTSCI		AGVLVPAKDQ		PGRQEKMSIY		QAMWKGVLRP		GTALVLLEAQ
AATGFVIDPV		RNLRLSVEEA		VAAGVVGGEI		QEKLLSAERA		VTGYTDPYTG
QQISLFQAMQ		KDLIVREHGI		RLLEAQIATG		GVIDPVHSHR		VPVDVAYRRG
YFDEEMNRVL		ADPSDDTKGF		FDPNTHENLT		YVQLLRRCVP		DPDTGLYMLQ
LAGRGSAVHQ		LSEELRCALR		DARVTPGSGA		LQGQSVSVWE		LLFYREVSED
RRQDLLSRYR		AGTLTVEELG		ATLTSLLAQA		QAQARAEAEA		GSPRPDPREA
LRAATMEVKV		GRLRGRAVPV		WDVLASGYVS		GAAREELLAE		FGSGTLDLPA
LTRRLTAIIE		EAEEAPGARP		QLQDAWRGPR		EPGPAGRGDG		DSGRSQREGQ
GEGETQEAAA		AAAAARRQEQ		TLRDATMEVQ		RGQFQGRPVS		VWDVLFSSYL
SEARRDELLA		QHAAGALGLP		DLVAVLTRVI		EETEERLSKV		SFRGLRRQVS
ASELHTSGIL		GPETLRDLAQ		GTKTLQEVTE		MDSVKRYLEG		TSCIAGVLVP
AKDQPGRQEK		MSIYQAMWKG		VLRPGTALVL		LEAQAATGFV		IDPVRNLRLS
VEEAVAAGVV		GGEIQEKLLS		AERAVTGYTD		PYTGQQISLF		QAMQKDLIVR
EHGIRLLEAQ		IATGGVIDPV		HSHRVPVDVA		YRRGYFDEEM		NRVLADPSDD
TKGFFDPNTH		ENLTYVQLLR		RCVPDPDTGL		YMLQLAGRGS		AVHQLSEELR
CALRDARVTP		GSGALQGQSV		SVWELLFYRE		VSEDRRQDLL		SRYRAGTLTV
EELGATLTSL		LAQAQAQARA		EAEAGSPRPD		PREALRAATM		EVKVGRLRGR
AVPVWDVLAS		GYVSGAAREE		LLAEFGSGTL		DLPALTRRLT		AIIEEAEEAP
GARPQLQDAW		RGPREPGPAG		RGDGDSGRSQ		REGQGEGETQ		EAAAAAAAAR
RQEQTLRDAT		MEVQRGQFQG		RPVSVWDVLF		SSYLSEARRD		ELLAQHAAGA
LGLPDLVAVL		TRVIEETEER		LSKVSFRGLR		RQVSASELHT		SGILGPETLR
DLAQGTKTLQ		EVTEMDSVKR		YLEGTSCIAG		VLVPAKDQPG		RQEKMSIYQA
MWKGVLRPGT		ALVLLEAQAA		TGFVIDPVRN		LRLSVEEAVA		AGVVGGEIQE
KLLSAERAVT		GYTDPYTGQQ		ISLFQAMQKD		LIVREHGIRL		LEAQIATGGV
IDPVHSHRVP		VDVAYRRGYF		DEEMNRVLAD		PSDDTKGFFD		PNTHENLTYV
QLLRRCVPDP		DTGLYMLQLA		GRGSAVHQLS		EELRCALRDA		RVTPGSGALQ
GQSVSVWELL		FYREVSEDRR		QDLLSRYRAS		TLTVEELGAT		LTSLLAQAQA
QARAEAEAGS		PRPDPREALR		AATMEVKVGR		LRGRAVPVWD		VLASGYVSRA
AREELLAEFG		SGTLDLPALT		RRLTAIIEEA		EEAPGARPQL		QDAWRGPREP
GPAGRGDGDS		GRSQREGQGE		GETQEAAAAT		AAARRQEQTL		RDATMEVQRG
QFQGRPVSVW		DVLFSSYLSE		ARRDELLAQH		AAGALGLPDL		VAVLTRVIEE
TEERLSKVSF		RGLRRQVSAS		ELHTSGILGP		ETLRDLAQGT		KTLQEVTEMD
SVKRYLEGTS		CIAGVLVPAK		DQPGRQEKMS		IYQAMWKGVL		RPGTALVLLE
AQAATGFVID		PVRNLRLSVE		EAVAAGVVGG		EIQEKLLSAE		RAVTGYTDPY
TGQQISLFQA		MQKDLIVREH		GIRLLEAQIA		TGGVIDPVHS		HRVPVDVAYR
RGYFDEEMNR		VLADPSDDTK		GFFDPNTHEN		LTYVQLLRRC		VPDPDTGLYM
LQLAGRGSAV		HQLSEELRCA		LRDARVTPGS		GALQGQSVSV		WELLFYREVS
EDRRQDLLSR		YRAGTLTVEE		LGATLTSLLA		QAQAQARAEA		EAGSPRPDPR
EALRAATMEV		KVGRLRGRAV		PVWDVLASGY		VSGAAREELL		AEFGSGTLDL
PALTRRLTAI		IEEAEEAPGA		RPQLQDAWRG		PREPGPAGRG		DGDSGRSQRE
GQGEGETQEA		AAAAAAARRQ		EQTLRDATME		VQRGQFQGRP		VSVWDVLFSS
YLSEARRDEL		LAQHAAGALG		LPDLVAVLTR		VIEETEERLS		KVSFRGLRRQ
VSASELHTSG		ILGPETLRDL		AQGTKTLQEV		TEMDSVKRYL		EGTSCIAGVL
VPAKDQPGRQ		EKMSIYQAMW		KGVLRPGTAL		VLLEAQAATG		FVIDPVRNLR
LSVEEAVAAG		VVGGEIQEKL		LSAERAVTGY		TDPYTGQQIS		LFQAMQKDLI
VREHGIRLLE		AQIATGGVID		PVHSHRVPVD		VAYRRGYFDE		EMNRVLADPS
DDTKGFFDPN		THENLTYLQL		LQRATLDPET		GLLFLSLSLQ

C: Cistein
D: Aspartat
E: Glutamat
F: Fenilalanin
G: Glicin
H: Histidin
I: Izoleucin
K: Lizin
L: Leucin
M: Metionin
N: Asparagin
P: Prolin
Q: Glutamin
R: Arginin
S: Serin
T: Treonin
V: Valin

W: Triptofan

Y: Tirozin

Funkcija

Utvrđeno je da se epiplakin veže za keratinske niti i može pridonijeti inhibiranju njihovog rasta. Sumnja se na to da se epiplakin vezan za keratin nalazi prvenstveno na granama i krajevima keratinskih niti. Blokiranje ekspresije epiplakina u kultiviranim epitelnim ćelijama rožnjače putem siRNK povezano je s bržim zatvaranjem rana i bržom migracijom rožnjačnih ćelija. To može biti posljedica gubitka epiplakina, što dovodi do modifikacije citoskeleta u epitelnim ćelijama.

Dopunska literatura

• Fujiwara S, Kohno K, Iwamatsu A, Naito I, Shinkai H (maj 1996). "Identification of a 450-kDa human epidermal autoantigen as a new member of the plectin family". The Journal of Investigative Dermatology. 106 (5): 1125–30. doi:10.1111/1523-1747.ep12340171. PMID 8618051.
• Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ, Mann M (mart 2003). "A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling". Nature Biotechnology. 21 (3): 315–8. doi:10.1038/nbt790. PMID 12577067. S2CID 26838266.
• Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J (maj 2003). "Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides". Nature Biotechnology. 21 (5): 566–9. doi:10.1038/nbt810. PMID 12665801. S2CID 23783563.
• Spazierer D, Fuchs P, Pröll V, Janda L, Oehler S, Fischer I, et al. (august 2003). "Epiplakin gene analysis in mouse reveals a single exon encoding a 725-kDa protein with expression restricted to epithelial tissues". The Journal of Biological Chemistry. 278 (34): 31657–66. doi:10.1074/jbc.M303055200. PMID 12791695.
• Takeo N, Wang W, Matsuo N, Sumiyoshi H, Yoshioka H, Fujiwara S (novembar 2003). "Structure and heterogeneity of the human gene for epiplakin (EPPK1)". The Journal of Investigative Dermatology. 121 (5): 1224–6. doi:10.1046/j.1523-1747.2003.12550_5.x. PMID 14708632.
• Kim JE, Tannenbaum SR, White FM (2005). "Global phosphoproteome of HT-29 human colon adenocarcinoma cells". Journal of Proteome Research. 4 (4): 1339–46. doi:10.1021/pr050048h. PMID 16083285.
• Nousiainen M, Silljé HH, Sauer G, Nigg EA, Körner R (april 2006). "Phosphoproteome analysis of the human mitotic spindle". Proceedings of the National Academy of Sciences of the United States of America. 103 (14): 5391–6. Bibcode:2006PNAS..103.5391N. doi:10.1073/pnas.0507066103. PMC 1459365. PMID 16565220.
• Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M (novembar 2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell. 127 (3): 635–48. doi:10.1016/j.cell.2006.09.026. PMID 17081983. S2CID 7827573.
• Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, et al. (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Molecular Systems Biology. 3 (1): 89. doi:10.1038/msb4100134. PMC 1847948. PMID 17353931.